MPX Bioceutical Corporation (CNSX: MPX) successfully completed $40-million secured convertible original issue discount loan financing. The proceeds of the Offering will be used primarily for accretive activities including capacity expansion, acquisitions and to support activities involved with securing new cannabis extraction, production and dispensary licenses in various jurisdictions in both the United States and Canada. "The pace of growth in our industry continues to accelerate with several U.S. states launching new cannabis legalization programs, the Canadian provinces designing and implementing retailing initiatives and acquisition opportunities arising on both sides of the border and, indeed globally. We have been introduced to multiple expansion opportunities and will be providing our shareholders and the market with an update on our progress on several of these in the next few days," says W. Scott Boyes Chairman, President and Chief Executive Officer of MPX Bioceutical.